Literature DB >> 10588936

Cardiovascular responses to angiotensins I and II in normotensive and hypertensive rats; effects of NO synthase inhibition or ET receptor antagonism.

S M Gardiner1, J E March, P A Kemp, T Bennett.   

Abstract

1. We compared the cardiovascular responses to angiotensins (I and II), and any possible modulatory influences thereupon of nitric oxide (NO) or endothelin (ET) in conscious male, normotensive, Hannover Sprague-Dawley (SD) rats, and hypertensive, heterozygous ((mRen-2)27), transgenic (TG) rats. 2. The pressor effects of angiotensin I or of angiotensin II were not consistently different in SD and TG rats. The accompanying absolute reductions in renal and mesenteric vascular conductances were smaller in TG rats, but probably due to the baseline vasoconstriction in those animals. 3. Inhibition of NO synthase with L-NAME had no significant effects on the pressor responses to angiotensin I or angiotensin II in either SD or TG rats. L-NAME reduced the absolute, but not percentage, reductions in renal and mesenteric vascular conductances in response to angiotensin I and angiotensin II. L-NAME abolished the hindquarters vasodilator effects of angiotensin I and angiotensin II in both strains of rat. 4. ET receptor antagonism (with SB209670) had no significant influence on the pressor or renal or mesenteric vasoconstrictor effects of angiotensin II in SD rats. In TG rats, the pressor responses to angiotensin II were unaffected by SB209670; the accompanying falls in renal and mesenteric vascular conductances were enhanced in absolute, but not in percentage terms. 5. These results provide no evidence for a buffering action of NO, or a modulatory influence of ET, on the pressor or vasoconstrictor effects of angiotensin I and/or angiotensin II in SD rats. Furthermore, there is no evidence for an altered sensitivity to angiotensin I or angiotensin II, and no evidence for a differential modulatory influence of either NO or ET in TG, compared to SD, rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588936      PMCID: PMC1571813          DOI: 10.1038/sj.bjp.0702978

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Effect of an endothelin antagonist on hemodynamic responses to angiotensin II.

Authors:  S M Balakrishnan; H D Wang; V Gopalakrishnan; T W Wilson; J R McNeill
Journal:  Hypertension       Date:  1996-11       Impact factor: 10.190

Review 2.  Paracrine regulation of the renal microcirculation.

Authors:  L G Navar; E W Inscho; S A Majid; J D Imig; L M Harrison-Bernard; K D Mitchell
Journal:  Physiol Rev       Date:  1996-04       Impact factor: 37.312

3.  Functional vascular renin-angiotensin system in hypertensive transgenic rats for the mouse renin gene Ren-2.

Authors:  S Arribas; C F Sánchez-Ferrer; C Peiró; A Ponte; M Salaices; J Marín
Journal:  Gen Pharmacol       Date:  1994-10

4.  Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene.

Authors:  A Moriguchi; K B Brosnihan; H Kumagai; D Ganten; C M Ferrario
Journal:  Am J Physiol       Date:  1994-04

5.  Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.

Authors:  S M Gardiner; J E March; P A Kemp; J J Mullins; T Bennett
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

6.  Angiotensin II: nitric oxide interaction and the distribution of blood flow.

Authors:  D H Sigmon; W H Beierwaltes
Journal:  Am J Physiol       Date:  1993-12

7.  Heterogeneity in vascular smooth muscle responsiveness to angiotensin II. Role of endothelin.

Authors:  L Chen; J R McNeill; T W Wilson; V Gopalakrishnan
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190

8.  In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670.

Authors:  S A Douglas; R M Edwards; J D Elliott; E H Ohlstein
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

9.  Nitric oxide synthase blockade and renal vascular responses to norepinephrine and endothelin-1 in conscious dogs.

Authors:  S M Fitzgerald; R G Evans; I J Christy; W P Anderson
Journal:  J Cardiovasc Pharmacol       Date:  1995-06       Impact factor: 3.105

10.  Endothelin in the kidney in malignant phase hypertension.

Authors:  C E Whitworth; M M Veniant; J D Firth; A D Cumming; J J Mullins
Journal:  Hypertension       Date:  1995-12       Impact factor: 10.190

View more
  1 in total

1.  Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.